METHODS	In this double-blind trial , patients with HIV infection were randomly assigned to receive either saquinavir ( 1800 mg per day ) plus both zidovudine ( 600 mg per day ) and zalcitabine ( 2.25 mg per day ) or zidovudine plus either saquinavir or zalcitabine .\